What Actually Counts as a Plateau
A GLP-1 plateau is several weeks of flat weight while you are still dosing on schedule, and most of what people call a plateau is not one. Two weeks is not a plateau. Two weeks is water, salt, a late dinner, a menstrual cycle, and a scale that reports all of it as fat. Give it six to eight weeks of honest weekly weigh-ins before you call it anything.
When it is real, the timing is usually unremarkable. STEP 4 is the trial that shows the shape best: 803 adults completed a 20-week run-in on semaglutide 2.4 mg with a mean loss of 10.6 percent, and those who stayed on the drug for the next 48 weeks lost a mean 7.9 percent more. Nearly four times the duration, less total loss. That is not failure, that is the normal geometry of the thing. Judged against the placebo group, which gained a mean 6.9 percent over the same 48 weeks, holding steady starts to look like work rather than stagnation.
Why the Curve Flattens
Weight loss slows on a GLP-1 mainly because a smaller body runs on less fuel than the one you started with. Lose 15 percent of your body weight and you are now carrying, heating and moving less mass all day. The intake that produced a deficit at month one can sit close to maintenance at month eight without you changing a single habit. Nothing about that requires the medication to have weakened.
Appetite is the second piece. GLP-1 treatment blunts hunger, it does not delete it, and the gap between a 600-calorie dinner and a 900-calorie dinner is smaller than most people estimate. If your gastrointestinal side effects have faded, which our GLP-1 side effects guide covers in detail, foods you avoided in month two may have quietly returned to your week.
You will also read that GLP-1 receptors desensitize over time, so the drug simply stops landing. We have not found that claim supported in the FDA prescribing information for Wegovy or Zepbound, or in the STEP and SURMOUNT trial reports. Treat it as a hypothesis people repeat, not as the explanation for your particular stall.
Check Where You Are in the Dose Schedule First
Before calling it a plateau, check whether you have actually reached a maintenance dose, because both labels build in months of titration. Plenty of people describe a plateau at a dose the manufacturer considers a step on the way up, not a destination. The schedules below come straight from the prescribing information.
| Medication | Starting dose | How it escalates | Maintenance dosage |
|---|---|---|---|
| Wegovy semaglutide injection |
0.25 mg once weekly for 4 weeks | Titrated every 4 weeks toward the maintenance dosage. If a dose is not tolerated during escalation, the label says to consider delaying escalation for 4 weeks. | 2.4 mg once weekly (recommended), with 1.7 mg once weekly also listed as a maintenance dosage in adults |
| Zepbound tirzepatide injection |
2.5 mg once weekly for 4 weeks, then 5 mg once weekly | Further increases in 2.5 mg increments after at least 4 weeks on the current dose | 5 mg, 10 mg or 15 mg once weekly, selected on treatment response and tolerability |
Source: US prescribing information for Wegovy (Novo Nordisk) and Zepbound (Eli Lilly). Dosing decisions belong to your prescriber, and this table is not a dosing instruction.
So if your weight went flat on semaglutide 1 mg or tirzepatide 5 mg, you may be mid-titration rather than stuck. That is a conversation with your prescriber, not a decision to make yourself. Escalating on your own, splitting doses to stretch a supply, or restarting at an old dose after a gap are all ways to turn a boring plateau into a genuine safety problem. If you are early in treatment and the schedule is still unfamiliar, our guide to your first month on a GLP-1 lays out how the ramp is meant to run.
The Muscle Problem Behind a Slow Scale
Some of what you lose on a GLP-1 is lean mass, and that is worth defending for reasons beyond the number on the scale. An exploratory body composition analysis from STEP 1, which used DEXA scans in a 140-person subgroup, reported that semaglutide reduced total fat mass by 19.3 percent and visceral fat mass by 27.4 percent from baseline, alongside a 9.7 percent reduction in lean body mass. Lean mass as a proportion of total body mass still rose by 3.0 percentage points, so the composition shifted in the right direction overall. The absolute lean loss is real all the same.
The joint advisory on nutritional priorities for GLP-1 therapy, published on 30 May 2025 by the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association and The Obesity Society, names adequate protein intake together with strength training as one of its eight priorities for preserving lean mass. Note the pairing. Protein without resistance training is the half of the advice people actually follow, and it is the weaker half. Our guide to preventing muscle loss on GLP-1 medications sets out the training and protein targets in full. For how to hit protein when appetite is suppressed and food tolerance has narrowed, see our guide to foods to avoid on GLP-1 medications.
What Helps, and What Is Being Sold to You
The honest answer is that nothing has been trialled specifically as a plateau-breaker, so be suspicious of anyone who says otherwise. Drug holidays to reset your receptors, microdosing protocols, detox supplements and compounded blends marketed as plateau fixes have no published evidence behind them, and compounded GLP-1 products carry their own regulatory problems, which our compounded GLP-1 guide sets out. If a clinic is pitching you a microdosing protocol, our guide to microdosing GLP-1s walks through what the labels and the FDA actually say about it. What remains are unglamorous measures that are supported, or at least sensible, and that your prescriber can help you work through.
- Confirm you have completed titration to a maintenance dosage under your prescriber's direction, rather than stalling partway up.
- Add resistance training and raise protein, as the 2025 joint advisory recommends, instead of cutting calories further.
- Track intake honestly for two weeks. Portions drift upward as nausea fades, and almost nobody notices it happening.
- Measure something other than weight. Waist circumference and how clothes fit can move while the scale sits still.
- Ask whether a different molecule is worth discussing. Our semaglutide vs tirzepatide comparison covers what separates them.
- Review other medications, sleep, alcohol and any new medical condition with your clinician before assuming the GLP-1 is the variable that changed.
Bring These Six Things to Your Prescriber
A plateau is a reason to book an appointment, not a reason to quietly stop refilling. Bring your current dose and the date you reached it, eight weeks of weights rather than yesterday's, a rough record of what you are eating, your current activity including any resistance training, any side effects that changed recently, and what you want the next six months to look like. That last one matters more than people expect, because maintaining a 15 percent loss and chasing another 5 percent are different goals with different plans.
If cost pressure is the real reason a plateau feels like the end of the road, work through the GLP-1 cost guide before you decide anything, and read what the withdrawal trials found in our guide to stopping a GLP-1 and weight regain. Stopping because the scale went quiet is the most expensive way to respond to a flat month.
Frequently Asked Questions
A flat scale on a GLP-1 usually means the fast part of the curve is over, not that the medication failed. In STEP 4, published in JAMA in 2021, participants lost a mean 10.6 percent of body weight during a 20-week run-in on semaglutide 2.4 mg, then lost a further 7.9 percent over the next 48 weeks on the same drug. The rate fell sharply while the treatment kept working. A smaller body also burns less energy at rest than the body you started with, so the same dose is now working against a lower requirement. Where you are in the dose schedule matters too, because both the Wegovy and Zepbound labels build in months of titration before the maintenance dose is reached.
There is no published figure for how long an individual plateau lasts, and any site giving you a number in weeks is guessing. The trials report group averages over fixed periods rather than the length of individual stalls. What the trials do show is that the slow phase can still be productive: in STEP 4 the 48 weeks after the run-in produced a further 7.9 percent mean loss, and in SURMOUNT-1, published in the New England Journal of Medicine in 2022, the 72-week means were 15.0 percent, 19.5 percent and 20.9 percent for tirzepatide 5 mg, 10 mg and 15 mg. Judge progress over months, not over a bad weigh-in.
That is your prescriber's decision, and the labels set the pace. The Wegovy prescribing information starts at 0.25 mg once weekly and titrates every 4 weeks toward a maintenance dosage of 2.4 mg, with 1.7 mg also listed as a maintenance option, and it advises considering a 4-week delay in escalation if a dose is not tolerated. The Zepbound prescribing information starts at 2.5 mg once weekly for 4 weeks, then 5 mg, with any further increases in 2.5 mg increments after at least 4 weeks on the current dose, and maintenance dosages of 5 mg, 10 mg or 15 mg chosen on treatment response and tolerability. Never escalate on your own, and never stretch supply by splitting doses.
Stalled? Get a Clinician to Look at the Whole Picture
Whether to hold, adjust, or change a GLP-1 is a medical decision, and a flat scale is exactly the kind of thing a prescriber should see the data behind. Licensed online programs include clinicians who can review your dose history, your side effects and your goals, then tell you whether anything should change.
Prescription required. Medical screening and clinician review required. Not all patients will qualify. Affiliate disclosure: this site may earn a referral fee from programs listed.
Compare Online GLP-1 ProgramsSources
The following sources were used for the trial results, dosing schedules and clinical guidance referenced on this page. Always verify against the most current version of each document.
- Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 2021: 20-week run-in mean weight loss of 10.6 percent, and weight change from week 20 to week 68 of minus 7.9 percent with continued semaglutide versus plus 6.9 percent with placebo.
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 2021: 1961 participants, mean weight change at week 68 of minus 14.9 percent with semaglutide 2.4 mg versus minus 2.4 percent with placebo.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine, 2022: mean weight change at week 72 of minus 15.0 percent, minus 19.5 percent and minus 20.9 percent with tirzepatide 5 mg, 10 mg and 15 mg.
- Wegovy (semaglutide) US Prescribing Information, Novo Nordisk: starting dosage, 4-week titration interval, maintenance dosages of 2.4 mg and 1.7 mg once weekly, and guidance on delaying escalation if a dose is not tolerated.
- Zepbound (tirzepatide) US Prescribing Information, Eli Lilly: 2.5 mg starting dosage, 2.5 mg increments after at least 4 weeks, and maintenance dosages of 5 mg, 10 mg and 15 mg once weekly selected on response and tolerability.
- Exploratory body composition analysis of the STEP 1 trial (DEXA subgroup of 140 participants): reductions from baseline of 19.3 percent in total fat mass, 27.4 percent in visceral fat mass and 9.7 percent in lean body mass, with lean body mass as a proportion of total body mass rising 3.0 percentage points.
- Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association and The Obesity Society, published 30 May 2025: adequate protein intake and strength training to preserve lean mass.